Authors: Rajiv Bahl and Anup Anvikar
Fifteen years ago, India reported more than 1,000 malaria deaths a year. In 2025, reported deaths were in double digits, a fall of more than 90%. Between 2015 and 2025 alone, malaria cases and deaths fell by nearly 80%, and the number of high-burden districts shrank from 155 to 33. In 160 districts, not a single locally acquired case was recorded between 2022 and 2025. India now aims for zero indigenous cases by 2027 and elimination by 2030.
Yet experience has shown that the last mile is the hardest, and the most dangerous place to grow complacent. India learnt this the hard way. The ICMR-National Institute of Malaria Research (ICMR-NIMR), which enters its 50th year in 2026, was born out of that lesson.
Born of a hard lesson
At Independence, malaria was endemic across almost the entire country. It caused an estimated 75 million cases and 8 lakh deaths a year. The National Malaria Eradication Programme, launched in 1958, used DDT spraying and chloroquine to bring cases down to about one lakh by 1965, with no reported deaths. Elimination seemed within reach.
Then malaria came back. Mosquitoes grew resistant to DDT, the parasite began to resist chloroquine, and funding and vigilance slipped as the disease receded. By 1976, cases had climbed to 6.4 million. The resurgence proved that insecticides and drugs alone were not enough: India needed its own science on the mosquito, the parasite and the people at risk.
In 1977, the government set up the Malaria Research Centre in Delhi under the Indian Council of Medical Research (ICMR). It was later upgraded to a national institute and renamed ICMR-NIMR in 2005.
Fifty years of answers
Malaria is caused by a parasite, but it reaches humans only through the bite of the female Anopheles mosquito. So the institute began with the vector: where it breeds, feeds, rests and bites. One of its most important findings was that mosquitoes that look identical can belong to different sibling species. Some prefer human blood and transmit malaria efficiently; others feed mainly on cattle and pose little risk. Telling them apart let control efforts be aimed where transmission actually happens.
Over five decades, the institute mapped Anopheles species across the country and tracked their resistance to insecticides. Its field projects showed that communities could cut malaria through environmental management and larvivorous fish. Its monitoring of how well medicines worked gave India the evidence to move from chloroquine to artemisinin-based combination therapy. It tested bed nets and rapid tests in real field conditions before they were scaled up nationally.
Its Comprehensive Case Management Project (CCMP), run with the Odisha government in four districts from 2013, showed that universal access to testing and complete treatment, backed by stronger surveillance, could sharply cut malaria even in hard-to-reach areas. Odisha built CCMP's lessons into its DAMaN programme for remote communities, which helped drive the steep fall in the state's malaria cases, and with it India's.
From mosquito to parasite, from lab to field, from microscopes to genomics and artificial intelligence, each discovery has brought India closer to the goal. Fifty years ago, the challenge was to understand malaria. Today, it is to end it.
Why the last mile is the hardest
We are now closer than ever, and that is exactly when the risk is greatest. As cases fall, it is tempting to believe the job is done. It is not. Just 33 districts in nine states and Union Territories still account for 64% of India's cases and 54% of its deaths. The last cases hide in remote, forested villages and in people with few or no symptoms. The parasite and the mosquito keep adapting.
Science alone will not close this gap. Research must also understand people: how remote communities perceive fever, when they seek care and whether they adopt prevention. But to finish the job, research and development must deliver in five areas.
Five priorities for the next decade
First, research must track the vector in a changing climate. Rising temperatures and shifting rainfall are changing where mosquitoes breed, how fast parasites develop inside them and how long the transmission season lasts. Malaria could return to areas that have been cleared of it, or reach higher altitudes. Invasive vectors such as Anopheles stephensi, which thrives in urban water containers, add a new risk. Continuous entomological surveillance, linked to climate data and forecasting models, must tell programmes where the next outbreak is likely, before it happens.
Second, prevention must keep working. Long-lasting insecticidal nets and indoor spraying have driven much of India's success, but the nets used in India rely largely on one class of insecticides, and mosquitoes are becoming resistant to them. Research must test and introduce new insecticide classes and next-generation nets, and expand biological tools such as larvivorous fish and bacterial larvicides. Just as important, these must be tools that communities will actually use.
Third, diagnosis must keep pace with a shrinking disease. Rapid diagnostic tests (RDTs) have brought reliable diagnosis to villages without laboratories, and they remain the backbone of malaria testing. But as cases fall, the remaining infections are fewer, milder and harder to detect. In some regions, a small share of the deadliest parasite, Plasmodium falciparum, carries genetic changes that can escape the protein most RDTs detect. Ongoing surveillance will keep current tests accurate where they are used, while research develops more sensitive, affordable tests for the low-transmission era. Microscopy remains the gold standard, but it depends on good equipment and trained technicians; AI-assisted and advanced microscopy can make diagnosis faster, more consistent and less dependent on scarce expertise.
Fourth, new medicines must be ready before resistance spreads. Chloroquine, once the mainstay of treatment, stopped working against the parasite in much of India. Artemisinin-based combinations replaced it, and they still work well here, but partial resistance to artemisinin has already emerged elsewhere in Asia and in Africa. Scientists must keep checking how well medicines perform across the country, and new antimalarials must move from the laboratory to clinical trials now. Shorter, safer cures for Plasmodium vivax, which can relapse months after infection, are just as urgent.
Finally, prevention is always better than cure, and India needs a malaria vaccine of its own. ICMR has developed AdFalciVax, India's first homegrown malaria vaccine candidate, and studies of its safety and effectiveness are under way. Future vaccines must suit India's own mix of parasites, including candidates that block transmission from person to mosquito, so that immunity protects whole communities and not only individuals.
Within reach
Behind every discovery is a simple purpose: to save lives. We are working toward the day when no family in India loses a child, a wage or a school day to a mosquito bite. That day is within reach. Once before, India came close and let malaria slip away. This time, we are determined not to.
Dr Rajiv Bahl is Secretary, Department of Health Research, and Director General, ICMR. Dr Anup Anvikar is Additional Director General, ICMR.